Table 3 Rash management Target population: Safety

Number of safety analysis set

34

28

6

68

Rash

19 (55.88)

14 (50.00)

2 (33.33)

35 (51.47)

Patients who received supportive care for rash

 Oral antihistamine

11 (57.89)

6 (42.86)

1 (50.00)

18 (51.43)

 Systemic corticosteroid

0 (0.00)

3 (21.43)

0 (0.00)

3 (8.57)

 Topical corticosteroid

13 (68.42)

13 (92.86)

1 (50.00)

27 (77.14)

 Drug interruption

11 (57.89)

6 (42.86)

1 (50.00)

18 (51.43)

 Dose reduction

4 (21.05)

3 (21.43)

0 (0.00)

7 (20.00)

 Drug discontinuation

3 (15.79)

2 (14.29)

0 (0.00)

5 (14.29)

 Other

2 (10.53)

1 (7.14)

0 (0.00)

3 (8.57)